Surgical treatment of pancreatic adenocarcinoma using cephalic duodenopancreatectomy (Part 2). Long term follow up after 204 cases;Tratamiento quirúrgico del adenocarcinoma pancreático mediante duodenopancreatectomía cefálica (parte 2). Seguimiento a largo plazo tras 204 casos

Cirugia Espanola

Volumn 88, Issue 6, 2010, Pages 374-382

  Fabregat, Juan ^a   Busquets, Juli ^a   Peláez, Núria ^a   Jorba, Rosa ^a   García Borobia, Francisco ^a   Masuet, Cristina ^a   Valls, Carlos ^a   Ruiz Osuna, Sandra ^a   Serrano, Teresa ^a   Galán, Maica ^a   Cambray, María ^a   Laquente, Berta ^a   Ramos, Emilio ^a   Rafecas, Antoni ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Cephalic duodenopancreatectomy; Long term survival; Pancreas cancer surgery; Pancreatic adenocarcinoma; Pancreatic cancer

Indexed keywords

EID: 78649717032     PISSN: 0009739X     EISSN: 1578147X     Source Type: Journal    
DOI: 10.1016/j.ciresp.2010.09.003     Document Type: Article

References (70)

1. Bramhall SR, Allum WH, Jones AG, Allwood A, Cummins C, Neoptolemos JP Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br J Surg 1995, 82:111-115.
2. Sener SF, Fremgen A, Menck HR, Winchester DP Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 1999, 189:1-7.
3. Bramhall SR, Allum WH, Jones AG, Allwood A, Cummins C, Professor J.P. Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br J Surg 1995, 82:111-115.
4. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ Cancer statistics. Cancer J Clin 2003, 53:5-26.
5. Abrams RA, Yeo CJ Combined modality adjuvant therapy for resected periampullary pancreatic and nonpancreatic adenocarcinoma: a review of studies and experience at The Johns Hopkins Hospital, 1991-2003. Surg Oncol Clin N Am 2004, 13:621-638.
6. Brennan MF Adjuvant therapy following resection for pancreatic adenocarcinoma. Surg Oncol Clin N Am 2004, 13:555-566.
7. Abrams RA Adjuvant therapy for pancreatic adenocarcinoma: what have we learned since 1985?. Int J Radiat Oncol Biol Phys 2003, 56(4 Suppl):3-9.
8. Okusaka T, Kosuge T Systemic chemotherapy for pancreatic cancer. Pancreas 2004, 28:301-304.
9. Kalser MH, Ellenberg SS Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985, 120:899-903.
10. Klinkenbijl JH, Jeekel H, Sahmoud T Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase iii trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999, 230:776-784.
11. Bakkevold KE, Arnesjo B, Dahl O, Kambestad B Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater - results of a controlled, prospective, randomised multicenter study. Eur J Cancer 1993, 29A:698-703.
12. Takada T, Amano H Yasuda Hea. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? a phase iii multicenter prospective randomized controlled trial in patients with resected pancreatico-biliary carcinoma. Cancer 2002, 95:1685-1695.
13. Neoptolemos JP, Stocken DD, Friess H, Bassi C., Dunn J.A., Hickey H., et al. A randomized trial of chemoradiotherapy and chemotherapy after resectioin of pancreatic cancer. N Engl J Med 2004, 350:1200-1210.
14. Valls C Obstructive Jaundice: diagnostic and therapeutic management. J Radiol 2006, 87(4 Pt 2):460-478.
15. Valls C, Andia E, Sánchez A, Fabregat J, Pozuelo O, Quintero JC, et al. Dual-phase helical CT of pancreatic adenocarcinoma: assessment of resectability before surgery. AJR Am J Roentgenol 2002, 178:821-826.
16. Nakao A, Harada A, Nonami T, Kaneko T, Inoue S, Takagi H Clinical significance of portal invasion by pancreatic head carcinoma. Surgery 1995, 117:50-55.
17. Ishikawa O, Ohigashi H, Imaoka S, Furukawa H, Sasaki Y, Fujita M, et al. Preoperative indications for extended pancreatectomy for locally advanced pancreas cancer involving the portal vein. Ann Surg 1992, 215:231-236.
18. Ishikawa O, Ohigashi H, Sasaki Y, Kabuto T, Furukawa H, Nakamori S, et al. Practical grouping of positive lymph nodes in pancreatic head cancer treated by an extended pancreatectomy. Surgery 1997, 121:244-249.
19. Yeo CJ, Cameron JL, Sohn TA, Coleman J, Sauter PK, Hruban RH, et al. Pancreaticoduodenectomy with or without extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma: comparison of morbidity and mortality and short-term outcome. Ann Surg 1999, 229:613-622. discussion 622-614.
20. Doi R, Kami K, Ito D, Fujimoto K, Kawaguchi Y, Wada M, et al. Prognostic implication of para-aortic lymph node metastasis in resectable pancreatic cancer. World J Surg 2007, 31:147-154.
21. Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Buchler MW Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 2004, 91:586-594.
22. Lillemoe KD, Pitt HA Palliation. Surgical and otherwise. Cancer 1996, 78(3 Suppl):605-614.
23. Yeo TP, Hruban RH, Leach SD, Wilentz RE, Sohn TA, Kern SE, et al. Pancreatic cancer. Curr Probl Cancer 2002, 26:176-275.
24. Li S, Zhuang GY, Pei YQ, Li CY, Wang JL, Ding W, et al. Extended local resection for treatment of periampullary carcinoma of vater. Hepatobiliary Pancreat Dis Int 2004, 3:303-306.
25. McCulloch P, Nita ME, Kazi H, Gama-Rodrigues J Extended versus limited lymph nodes dissection technique for adenocarcinoma of the stomach. Cochrane Database Syst Rev 2004, CD001964.
26. Yeo CJ, Cameron JL, Lillemoe KD, Sohn TA, Campbell KA, Sauter PK, et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled tial evaluating survival, morbidity, and mortality. Ann Surg 2002, 236:355-366. discussion 366-8.
27. Tran KT, Smeenk HG, van Eijck CH, Kazemier G, Hop WC, Greve JW, et al. Pylorus preserving pancreaticoduodenectomy versus standard Whipple procedure: a prospective, randomized, multicenter analysis of 170 patients with pancreatic and periampullary tumors. Ann Surg 2004, 240:738-745.
28. Nguyen TC, Sohn TA, Cameron JL, Lillemoe KD, Campbell KA, Coleman J, et al. Standard vs. radical pancreaticoduodenectomy for periampullary adenocarcinoma: a prospective, randomized trial evaluating quality of life in pancreaticoduodenectomy survivors. J Gastrointest Surg 2003, 7:1-9. discussion 9-11.
29. Nakeeb A, Lillemoe KD, Grosfeld JL Surgical techniques for pancreatic cancer. Minerva Chir 2004, 59:151-163.
30. Hirano S, Kondo S, Ambo Y, Tanaka E, Morikawa T, Okushiba S, et al. Outcome of duodenum-preserving resection of the head of the pancreas for intraductal papillary-mucinous neoplasm. Dig Surg 2004, 21:242-245.
31. Luttges J, Vogel I, Menke M, Henne-Bruns D, Kremer B, Kloppel G The retroperitoneal resection margin and vessel involvement are important factors determining survival after pancreaticoduodenectomy for ductal adenocarcinoma of the head of the pancreas. Virchows Arch 1998, 433:237-242.
32. Westgaard A, Tafjord S, Farstad IN, Cvancarova M, Eide TJ, Mathisen O, et al. Resectable adenocarcinomas in the pancreatic head: the retroperitoneal resection margin is an independent prognostic factor. BMC Cancer 2008, 8:5.
33. Staley CA, Cleary KR, Abbruzzese JL, Lee JE, Ames FC, Fenoglio CJ, et al. The need for standardized pathologic staging of pancreaticoduodenectomy specimens. Pancreas 1996, 12:373-380.
34. Howard TJ, Krug JE, Yu J, Zyromski NJ, Schmidt CM, Jacobson LE, et al. A margin-negative R0 resection accomplished with minimal postoperative complications is the surgeon's contribution to long-term survival in pancreatic cancer. J Gastrointest Surg 2006, 10:1338-1345. discussion 1345-1336.
35. Soriano-Izquierdo A, Castells A, Pellise M, Ayuso C, Ayuso JR, de Caralt TM, et al. Hospital registry of pancreatic tumors. Experience of the Hospital Clinic in Barcelona (Spain). Gastroenterol Hepatol 2004, 27:250-255.
36. Boadas J, Balart J, Capella G, Lluis F, Farre A Survival of cancer of the pancreas. Bases for new strategies in diagnosis and therapy. Rev Esp Enferm Dig 2000, 92:316-325.
37. Fernández-Cruz L, Cosa R, Blanco L, Levi S, López-Boado MA, Navarro S Curative laparoscopic resection for pancreatic neoplasms: a critical analysis from a single institution. J Gastrointest Surg 2007, 11:1607-1621. discussion 1621-1602.
38. Sabater L, Calvete J, Aparisi L, Cánovas R, Muñoz E, Añón R, et al. Neoplasias de páncreas y periampulares: morbimortalidad, resultados funcionales y supervivencia a largo plazo. Cir Esp 2009, 3:159-166.
39. Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000, 4:567-579.
40. Evans DB, Hess KR, Pisters PW ESPAC-1 trial of adjuvant therapy for resectable adenocarcinoma of the pancreas. Ann Surg 2002, 236:694. author reply 694-696.
41. Wayne JD, Abdalla EK, Wolff RA, Crane CH, Pisters PW, Evans DB Localized adenocarcinoma of the pancreas: the rationale for preoperative chemoradiation. Oncologist 2002, 7:34-45.
42. Pedrazzoli S, DiCarlo V, Dionigi R, Mosca F, Pederzoli P, Pasquali C, et al. Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group. Ann Surg 1998, 228:508-517.
43. Allison DC, Bose KK, Hruban RH, Piantadosi S, Dooley WC, Boitnott JK, et al. Pancreatic cancer cell DNA content correlates with long-term survival after pancreatoduodenectomy. Ann Surg 1991, 214:648-656.
44. Fujioka S, Yoshida K, Yanagisawa S, Kawakami M, Aoki T, Yamazaki Y Angiogenesis in pancreatic carcinoma: thymidine phosphorylase expression in stromal cells and intratumoral microvessel density as independent predictors of overall and relapse-free survival. Cancer 2001, 92:1788-1797.
45. Cameron JL, Crist DW, Sitzmann JV, Hruban RH, Boitnott JK, Seidler AJ, et al. Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am J Surg 1991, 161:120-124. discussion 124-125.
46. Takahashi S, Ogata Y, Miyazaki H, Maeda D, Murai S, Yamataka K, et al. Aggressive surgery for pancreatic duct cell cancer: feasibility, validity, limitations. World J Surg 1995, 19:653-659. discussion 660.
47. Pawlik TM, Abdalla EK, Barnett CC, Ahmad SA, Cleary KR, Vauthey JN, et al. Feasibility of a randomized trial of extended lymphadenectomy for pancreatic cancer. Arch Surg 2005, 140:584-589. discussion 589-591.
48. Pawlik TM, Gleisner AL, Cameron JL, Winter JM, Assumpcao L, Lillemoe KD, et al. Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery 2007, 141:610-618.
49. Birkmeyer JD, Finlayson SR, Tosteson AN, Sharp SM, Warshaw AL, Fisher ES Effect of hospital volume on in-hospital mortality with pancreaticoduodenectomy. Surgery 1999, 125:250-256.
50. Birkmeyer JD, Warshaw AL, Finlayson SR, Grove MR, Tosteson AN Relationship between hospital volume and late survival after pancreaticoduodenectomy. Surgery 1999, 126:178-183.
51. Raut CP, Tseng JF, Sun CC, Wang H, Wolff RA, Crane CH, et al. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg 2007, 246:52-60.
52. Stephenson KR, Steinberg SM, Hughes KS, Vetto JT, Sugarbaker PH, Chang AE Perioperative blood transfusions are associated with decreased time to recurrence and decreased survival after resection of colorectal liver metastases. Ann Surg 1988, 208:679-687.
53. Yeo CJ, Cameron JL, Maher MM, Sauter PK, Zahurak ML, Talamini MA, et al. A prospective randomized trial of pancreaticogastrostomy versus pancreaticojejunostomy after pancreaticoduodenectomy. Ann Surg 1995, 222:580-588. discussion 588-592.
54. Kazanjian KK, Hines OJ, Duffy JP, Yoon DY, Cortina G, Reber HA Improved survival following pancreaticoduodenectomy to treat adenocarcinoma of the pancreas: the influence of operative blood loss. Arch Surg 2008, 143:1166-1171.
55. Ueda M, Endo I, Nakashima M, Minami Y, Takeda K, Matsuo K, et al. Prognostic factors after resection of pancreatic cancer. World J Surg 2009, 33:104-110.
56. DeOliveira ML, Winter JM, Schafer M, Cunningham SC, Cameron JL, Yeo CJ, et al. Assessment of complications after pancreatic surgery: A novel grading system applied to 633 patients undergoing pancreaticoduodenectomy. Ann Surg 2006, 244:931-937. discussion 937-939.
57. Yeh JJ, Gonen M, Tomlinson JS, Idrees K, Brennan MF, Fong Y Effect of blood transfusion on outcome after pancreaticoduodenectomy for exocrine tumour of the pancreas. Br J Surg 2007, 94:466-472.
58. Murakami Y, Uemura K, Sudo T, Hayashidani Y, Hashimoto Y, Ohge H, et al. Impact of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for adenocarcinoma of the body or tail of the pancreas. J Gastrointest Surg 2009, 13:85-92.
59. Farnell MB, Pearson RK, Sarr MG, DiMagno EP, Burgart LJ, Dahl TR, et al. A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery 2005, 138:618-628. discussion 628-630.
60. Riall TS, Cameron JL, Lillemoe KD, Campbell KA, Sauter PK, Coleman J, et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma--part 3: update on 5-year survival. J Gastrointest Surg 2005, 9:1191-1204. discussion 1204-1196.
61. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. Jama 2007, 297:267-277.
62. Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. Jama 2008, 299:1019-1026.
63. Bradley EL Long-term survival after pancreatoduodenectomy for ductal adenocarcinoma: the emperor has no clothes?. Pancreas 2008, 37:349-351.
64. Gordon TA, Burleyson GP, Tielsch JM, Cameron JL The effects of regionalization on cost and outcome for one general high-risk surgical procedure. Ann Surg 1995, 221:43-49.
65. Glasgow RE, Mulvihill SJ Hospital volume influences outcome in patients undergoing pancreatic resection for cancer. West J Med 1996, 165:294-300.
66. Nordback L, Parviainen M, Raty S, Kuivanen H, Sand J Resection of the head of the pancreas in Finland: effects of hospital and surgeon on short-term and long-term results. Scand J Gastroenterol 2002, 37:1454-1460.
67. Guidelines for the management of patients with pancreatic cancer periampullary and ampullary carcinomas. Gut. 2005;54 (Suppl 5): v1-16.
68. NCCN practice guidelines for pancreatic cancer. Oncology (Williston Park). 1997;11(11A): 41-55.
69. DiMagno EP, Reber HA, Tempero MA AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association. Gastroenterology 1999, 117:1464-1484.
70. Katz MH, Wang H, Fleming JB, Sun CC, Hwang RF, Wolff RA, et al. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol 2009, 16:836-847.